MUMBAI, India, Feb. 13 -- Intellectual Property India has published a patent application (202611001292 A) filed by Guru Kashi University, Bathinda, Punjab, on Jan. 6, for 'multi-pathway modulatory herbal formulation for therapeutic management of ovarian serous cystadenocarcinoma (osca).'
Inventor(s) include Anupam Sharma; Anil Kumar Sharma; Amanpreet Singh; and Lokender Kashyap.
The application for the patent was published on Feb. 13, under issue no. 07/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to polyherbal formulation designed with a combination of selected bioactive phytochemicals from five medicinal plants, Nigella sativa, Murraya koenigii, Azadirachta indica, Syzygium cumini, and Silybum marianum, for the treatment of Ovarian Serous Cystadenocarcinoma (OSCA). The formulation contains the ten selected compounds: Thymoquinone, Nigellidine, Mahanimbine, Koenimbine, Quercetin, Catechin, Ellagic Acid, Gallic Acid, Silibinin, and Isosilybin A, with the selection of these ten compounds being based on their known pharmacological properties and predicted ability to target cancer. This invention uses an integrative computational way to identify and confirm the potential molecular targets of the herbal formulation. Using Swiss Target Prediction, the targets of the individual phytochemicals were identified, while OSCA-associated overexpressed genes were obtained from GEPIA2. Comparative analysis revealed 124 overlapping genes representing the predicted targets of the polyherbal composition in the context of OSCA. A protein-protein interaction (PPI) network was constructed, and KEGG pathway enrichment analysis identified multiple cancer-related signalling pathways modulated by the formulation."
Disclaimer: Curated by HT Syndication.
